Stephen Ray Mitchell Sells 5,000 Shares of Vanda Pharmaceuticals Inc. Stock
VNDA Stock | USD 5.09 0.15 3.04% |
About 58% of all Vanda Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Vanda Pharmaceuticals suggests that some traders are interested. The current market sentiment, together with Vanda Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Vanda Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Vanda |
Vanda Pharmaceuticals Inc. Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of 5.17, for a total transaction of 25,850.00. Following the completion of the sale, the director now owns 44,857
Read at thelincolnianonline.com
Vanda Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Vanda Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Vanda Pharmaceuticals Fundamental Analysis
We analyze Vanda Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vanda Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vanda Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Vanda Pharmaceuticals is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Vanda Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vanda Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Vanda Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vanda Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Vanda Pharmaceuticals Related Equities
REPL | Replimune | 35.11 | ||||
TSVT | 2Seventy Bio | 14.24 | ||||
GPCR | Structure Therapeutics | 11.00 | ||||
TIL | Instil Bio | 5.61 | ||||
LQDA | Liquidia Technologies | 4.93 | ||||
NUVB | Nuvation Bio | 3.70 | ||||
CYTK | Cytokinetics | 3.00 | ||||
LEGN | Legend Biotech | 2.99 | ||||
RCUS | Arcus Biosciences | 2.94 | ||||
CGEM | Cullinan Oncology | 2.62 | ||||
RLAY | Relay Therapeutics | 2.37 | ||||
STOK | Stoke Therapeutics | 1.42 | ||||
BMRN | Biomarin Pharmaceutical | 1.28 | ||||
CNTB | Connect Biopharma | 1.01 | ||||
TECH | Bio Techne | 0.32 | ||||
PCVX | Vaxcyte | 0.17 | ||||
RVMD | Revolution Medicines | 0.05 | ||||
ANNX | Annexon | 0.58 | ||||
PHAT | Phathom Pharmaceuticals | 1.16 | ||||
KZR | Kezar Life | 1.57 | ||||
BPMC | Blueprint Medicines | 2.56 |
Complementary Tools for Vanda Stock analysis
When running Vanda Pharmaceuticals' price analysis, check to measure Vanda Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vanda Pharmaceuticals is operating at the current time. Most of Vanda Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vanda Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vanda Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vanda Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |